Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Methacycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 13/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.70 |
| ▸ | USP2 | O75604 | 9/20 | 0.70 |
| ▸ | RECQL | P46063 | 8/20 | 0.70 |
| ▸ | HPGD | P15428 | 8/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.70 |
| ▸ | THRB | P10828 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.70 |
| ▸ | MC4R | P32245 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 7/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | RAD52 | P43351 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacycline SCHEMBL21133469 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2RECQLHPGD | |
| Methacycline SCHEMBL4014 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2RECQLHPGD | |
| Methacycline SCHEMBL13328119 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2RECQLHPGD | |
| Methacycline SCHEMBL4016 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2RECQLHPGD | |
| Methacycline SCHEMBL19771282 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2RECQLHPGD | |
| Methacycline SCHEMBL17430778 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2RECQLHPGD | |
| Methacycline SCHEMBL2614978 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2RECQLHPGD | |
| Methacycline SCHEMBL29376851 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2RECQLHPGD | |
| Methacycline SCHEMBL127703 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2RECQLHPGD | |
| Methacycline SCHEMBL5445227 | 0.99 | TDP1 (0.70) | TDP1KDM4EUSP2RECQLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-9562003-B2 | Methods of using substituted tetracycline compounds to modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562003-B2 | Methods of using substituted tetracycline compounds to modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20150321997-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150321997-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20140343020-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC (US) | 2014-11-20 | — | — | US | disclosed |
| US-7960366-B2 | Tetracycline compound of given formula, an antifungal agent such as amphotericin B and a carrier; treating fungal infections | PARATEK PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960366-B2 | Tetracycline compound of given formula, an antifungal agent such as amphotericin B and a carrier; treating fungal infections | PARATEK PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7696187-B2 | Methods of preparing substituted tetracyclines with transition metal-based chemistries | TRUSTEES OF TUFTS COLLEGE (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696187-B2 | Methods of preparing substituted tetracyclines with transition metal-based chemistries | TRUSTEES OF TUFTS COLLEGE (US) | 2010-04-13 | — | — | US | disclosed |
| US-7414041-B2 | Reducing tetracycline resistance in living cells | TRUSTEES OF TUFTS COLLEGE (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080118979-A1 | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080118979-A1 | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070072834-A1 | 13-Substituted methacycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072834-A1 | 13-Substituted methacycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2004038000-A2 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150321997-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | TDP1 999/4885KDM4E 1013/4885USP2 1487/4885 |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | TDP1 999/4885KDM4E 1013/4885USP2 1487/4885 |
| US-20140343020-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | TDP1 999/4885KDM4E 1013/4885USP2 1487/4885 |
| US-20070072834-A1 | 13-Substituted methacycline compounds | TET3, TET1, TPMT | TDP1 2190/4885KDM4E 1560/4885USP2 2846/4885 |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | TDP1 1003/4885KDM4E 3572/4885USP2 2358/4885 |
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | TDP1 1003/4885KDM4E 3572/4885USP2 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.